By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators discuss new findings in Oncology. According to news reporting out of Shanghai, People's Republic of China, by NewsRx editors, research stated, "Tumor metastasis is the leading cause of breast cancer-related mortality and remains to be the principal obstacle for the successful chemotherapy of breast cancer. To block metastasis of breast cancer, silibinin-loaded lipid nanoparticles (SLNs) containing TPGS and phosphatidylcholine were designed and prepared by a thin-film hydration method."
Our news journalists obtained a quote from the research from the Chinese Academy of Science, "The optimized SLNs were approximately 45 nm in particle size with high stability in serum, which were further demonstrated to be efficiently uptaken by MDA-MB-231 breast cancer cells. Importantly, the SLNs could accumulate within tumor tissues with high efficiency and amounts. Compared with free silibinin, SLNs exhibited much stronger inhibitory effects on the invasion and migration of MDA-MB-231 cells through the downregulation of MMP-9 and Snail. More importantly, systematic in vivo evaluations demonstrated that SLNs treatment group resulted in 67% and 39% less pulmonary metastases formation than saline treatment group in the spontaneous and blood vessel metastasis models, respectively. Interestingly, the blank lipid nanoparticles without silibinin were also found, for the first time, to possess the efficient anti-metastatic capabilities to some extent. The biocompatibility assay reveals that SLNs treatment did not exhibit obvious systemic toxicity in two mouse models."
According to the news editors, the research concluded: "Therefore, SLNs are the promising delivery systems against metastasis of breast cancer cells."
For more information on this research see: Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS. International Journal of Pharmaceutics, 2013;454(1):21-30. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)
Our news journalists report that additional information may be obtained by contacting P.F. Xu, Chinese Academy Sci, Shanghai Inst Mat Med, Center Pharmaceut, Shanghai 201203, People's Republic of China. Additional authors for this research include Q. Yin, J.N. Shen, L.L. Chen, H.J. Yu, Z.W. Zhang and Y.P. Li (see also Oncology).
Keywords for this news article include: Asia, Shanghai, Oncology, Treatment, Nanoparticle, Breast Cancer, Nanotechnology, Women's Health, Emerging Technologies, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC